Marina Chiara Garassino, MD

Articles

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

May 16th 2023

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

May 9th 2023

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

May 9th 2023

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Updates in Gender-Based Treatment for Patients with Advanced NSCLC

May 2nd 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.

CTLA-4 Targeted Regimens in Advanced NSCLC

April 26th 2023

Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.

Subgrouping Patients with Advanced NSCLC for Tailored Treatment

April 25th 2023

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Overview of PD-L1 Testing in Advanced NSCLC

April 25th 2023

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC

October 21st 2022

Marina Chiara Garassino, MD, discusses updates from the phase 3 KEYNOTE-189 trial in non–small cell lung cancer.

Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC

September 24th 2021

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC

September 18th 2021

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.

Dr. Garassino on Safety Protocols for Patients With Cancer in Italy During COVID-19

May 13th 2021

Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

Dr. Garassino on the Rationale for the PACIFIC-6 Trial in NSCLC

March 25th 2021

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

Dr. Garassino on COVID-19 Vaccine Distribution to Patients With Cancer in Italy

February 25th 2021

Marina Garassino, MD, discusses the distribution of the coronavirus disease 2019 vaccine to patients with cancer in Italy.

Dr. Garassino on Erlotinib/Ramucirumab Versus Osimertinib in EGFR+ NSCLC

June 13th 2019

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the combination of erlotinib (Tarceva) and ramucirumab (Cyramza) versus osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Garassino Discusses PROs With Durvalumab by PD-L1 Expression in Stage III NSCLC

April 25th 2019

Marina Chiara Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses patient reported outcomes with durvalumab by PD-L1 expression in patients with stage III unresectable non–small cell lung cancer.

Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

April 12th 2018

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

November 1st 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

October 31st 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

Dr. Garassino Discusses Recent Pivotal Immunotherapy Findings in NSCLC

October 19th 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

Dr. Garassino on the PACIFIC Trial for NSCLC

September 20th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).